Even more relevant, the authors also showed that the oral administration of PT2385, a selective HIF-2α antagonist that inhibits its transcriptional activity by blocking the heterodimerization between HIF-2α and HIF-1β, significantly prevented and reversed obesity and liver steatosis [137]. This evidence concerns the gene EPAS1 and fatty liver disease.